Jun 1, 2026 08:04AM Elicio Therapeutics publishes research on AMP-DNA adjuvant technology

May 11, 2026 05:13PM Elicio Therapeutics (ELTX) Misses Q1 EPS by 65c

Apr 15, 2026 06:36AM Ladenburg Thalmann Starts Elicio Therapeutics (ELTX) at Buy

Mar 24, 2026 10:30AM Advancements in Novel Immunotherapeutics in The Oncology Battle

Mar 13, 2026 06:44AM Elicio Therapeutics (ELTX) PT Raised to $17 at H.C. Wainwright

Mar 9, 2026 04:16PM Rodman & Renshaw Starts Elicio Therapeutics (ELTX) at Buy

Nov 13, 2025 06:49PM Elicio Therapeutics (ELTX) Misses Q3 EPS by 60c

Jul 17, 2025 06:44AM Elicio Therapeutics (ELTX) PT Raised to $13 at H.C. Wainwright

Jun 4, 2025 08:00AM Elicio Therapeutics (ELTX) Secures $10 Million in Financing

Mar 24, 2025 07:00AM Elicio Therapeutics (ELTX) Appoints Preetam Shah as Chief Strategy and Financial Officer

Jan 30, 2025 08:00AM Elicio Therapeutics (ELTX) Announces 1.26M Share Offering at $7.925/sh

Jan 22, 2025 07:30AM Elicio Therapeutics (ELTX) Reaches Alignment with FDA on ELI-002 Registrational Strategy

Dec 12, 2024 07:00AM Elicio Therapeutics (ELTX) Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study

Dec 3, 2024 07:01AM Elicio Therapeutics (ELTX) Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

Nov 13, 2024 04:25PM Elicio Therapeutics (ELTX) Files for 3.44M Share Offering by Selling Stockholders

Nov 7, 2024 04:08PM Elicio Therapeutics (ELTX) Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study

Oct 30, 2024 04:13PM Jones Trading Starts Elicio Therapeutics (ELTX) at Buy

Jun 28, 2024 09:01AM Elicio Therapeutics (ELTX) Prices $11.5M Offering at $5/sh

Jun 27, 2024 04:05PM Elicio Therapeutics (ELTX) Announces Proposed Share Offering

Jun 27, 2024 04:01PM Elicio Therapeutics (ELTX) Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P